Viewing Study NCT05903833


Ignite Creation Date: 2025-12-25 @ 2:45 AM
Ignite Modification Date: 2026-01-08 @ 7:13 AM
Study NCT ID: NCT05903833
Status: RECRUITING
Last Update Posted: 2025-09-09
First Post: 2023-05-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
Sponsor: AGO Research GmbH
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module